We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Palisade Bio Inc (PALI) USD0.01

Sell:$3.71 Buy:$3.95 Change: $0.23 (6.20%)
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
Sell:$3.71
Buy:$3.95
Change: $0.23 (6.20%)
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
Sell:$3.71
Buy:$3.95
Change: $0.23 (6.20%)
Market closed |  Prices as at close on 16 August 2024 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Palisade Bio, Inc. is a biopharmaceutical company focused on developing novel therapeutics for serious chronic gastrointestinal diseases. It is engaged in advancing a PALI-2108 for the treatment of IBD, including UC and CD and are researching PALI-1908. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract. UC primarily affects the colon and the rectum. CD can affect any part of the gastrointestinal tract, from the mouth to the anus. PALI-2108 is a prodrug PDE4 inhibitor that operates through a mechanism within colon tissues, targeting the key enzyme phosphodiesterase-4 (PDE4). This enzyme is pivotal in cAMP hydrolysis, and by inhibiting PDE4, intracellular cAMP levels are elevated. This elevation leads to the downregulation of inflammatory cytokines and a reduction in the expression of cell adhesion molecules. By modulating these processes, PALI-2108 prevents the local infiltration and activation of inflammatory cells in the colon tissues.

Contact details

Address:
7750 El Camino Real, Suite 5200
CARLSBAD
92009
United States
Telephone:
+1 (858) 7044900
Website:
https://palisadebio.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
PALI
ISIN:
US6963894026
Market cap:
$4.23 million
Shares in issue:
1.18 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • J. D. Finley
    Chief Executive Officer, Chief Financial Officer, Director
  • Robert Mcrae
    Chief Operating Officer
  • Mitchell Jones
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.